A new research paper released in Pediatrics examines the impact of administering high-dose erythropoietin (EPO) in conjunction with hypothermia therapy (brain cooling) for babies with hypoxic ischemic encephalopathy (HIE). The paper describes the result of Phase II clinical trials.
Background: Hypothermia Therapy as the Standard of Care for Treating HIE
The standard of care for babies diagnosed with hypoxic ischemic encephalopathy (HIE) is the administration of hypothermia therapy (either head cooling only, or whole-body cooling with a cooling pad or cooling blanket) within 6 hours* of the injury. Physicians must provide this treatment for HIE, or they are failing to meet an expected standard of care. This new research seeks to determine whether administering EPO will make hypothermia therapy even more effective in treating HIE than when it is used by itself.
The Study: Hypothermia Therapy and EPO Potentially More Effective Than Hypothermia Therapy Alone
The study examined the effect of using multiple doses of EPO together with hypothermia therapy to treat infants with moderate to severe encephalopathy and perinatal respiratory depression. To measure the effectiveness of the treatment, they looked at two different measures of brain injury: (1) brain injury severity as rated by two independent observers using MRI results and (2) developmental outcomes of the children at 1 year of age (as assessed by the Alberta Infant Motor Scale and the Warner Initial Developmental Scale).
MRI scans showed that infants who received EPO had a lower global brain injury score than those who did not receive EPO. Those who received EPO also had fewer instances of moderate/severe brain injury, subcortical injury, cerebellar injury, and had improved motor outcomes at 1 year of age. The motor testing results are preliminary, however, and must still be confirmed, as there is still a large range of what is considered ‘normal development’ at age 1. As the subjects age, tests will have clearer results.
The study suggests that high doses of EPO in conjunction with hypothermia resulted in less MRI brain injury and improved 1-year motor function than with hypothermia therapy alone.
Significance: EPO as an Inexpensive and Effective Additional Treatment?
Hypoxic ischemic encephalopathy (HIE) is the cause of more than 800,000 deaths worldwide. It causes thousands of cases of permanent brain damage every year in the U.S.—rates as high as 1 to 3 cases in 1,000. According to lead author Yvonne Wu, child neurologist and professor of Neurology and Pediatrics at UCSF Benioff Children’s Hospital San Francisco, “More than 40 percent of infants [with HIE] will die or suffer moderate to severe disabilities, including cerebral palsy, intellectual impairment and epilepsy…We wanted to find something that could amplify effectiveness.”
This study demonstrates that the treatment (as it was used in the study) is safe and that further, larger trials are warranted to further test the effects of EPO used together with hypothermia therapy. According to senior author Roberta Ballard, MD (a neonatologist and professor of Pediatrics at UCSF Benioff Children’s Hospital San Francisco):
“…There is a strong suggestion that the patients are doing better than would be expected long term…It would be very encouraging if we find that an inexpensive old drug, costing $60 per infusion, rather than a new drug that costs more than $2 billion to develop, may prevent untold suffering. A larger trial will allow a definitive answer to whether there should be a change in clinical care for this devastating condition (emphasis added).”
Legal Help for Babies with HIE
If your child was diagnosed with HIE, and you suspect this may be due to a medical staffe’s mistake, feel free to reach out to the dedicated birth injury attorneys at Reiter & Walsh ABC Law Centers. Our law firm focuses exclusively on birth injuries and has been helping children with birth injuries since the firm’s inception in 1997. Case evaluation is always free, and we will never charge any fees until we win your case.
Free Case Review | Available 24/7 | No Fee Until We Win
Brain research is an ongoing process, and, at the moment, hypothermia therapy is the standard of care when it comes to hypoxic ischemic encephalopathy. Additive or supplemental measures in addition to hypothermia are still in preclinical or clinical trials, so it is too early to say whether any of these supplemental measures will be adopted as standards of care. Because these are highly experimental findings, we caution readers that we are merely providing this information as an update on findings in the field of HIE research, rather than as a potential source of treatment information.